Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $23.15 and last traded at $26.12, with a volume of 350178 shares traded. The stock had previously closed at $24.53.
Analysts Set New Price Targets
IMCR has been the topic of a number of analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $71.00 price target on shares of Immunocore in a research report on Thursday, April 10th. JPMorgan Chase & Co. decreased their target price on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research report on Monday. Mizuho lowered their price target on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a report on Monday, April 7th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th. Finally, HC Wainwright reissued a "buy" rating and set a $100.00 target price on shares of Immunocore in a research note on Wednesday, March 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Immunocore has an average rating of "Moderate Buy" and a consensus target price of $63.73.
Check Out Our Latest Report on IMCR
Immunocore Stock Up 2.1 %
The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The stock's 50-day moving average price is $28.86 and its 200-day moving average price is $30.46. The company has a market cap of $1.37 billion, a P/E ratio of -28.87 and a beta of 0.75.
Insiders Place Their Bets
In other Immunocore news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the firm's stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the purchase, the director now owns 2,144,060 shares of the company's stock, valued at $63,721,463.20. This trade represents a 60.40 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 9.10% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. State Street Corp boosted its position in shares of Immunocore by 63.9% during the third quarter. State Street Corp now owns 76,671 shares of the company's stock valued at $2,387,000 after buying an additional 29,897 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Immunocore by 25.0% during the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock worth $17,007,000 after acquiring an additional 109,206 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in shares of Immunocore by 125.4% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company's stock worth $1,463,000 after acquiring an additional 27,598 shares in the last quarter. Crossmark Global Holdings Inc. raised its holdings in shares of Immunocore by 36.7% in the fourth quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company's stock valued at $1,121,000 after purchasing an additional 10,217 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock valued at $248,000 after purchasing an additional 960 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.
Immunocore Company Profile
(
Get Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Further Reading
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
